DBV has now started the Phase III Viaskin Peanut trial (PEPITES), which has been enlarged to meet patient and investigator demand, a positive sign for future potential uptake. The Phase II Viaskin Milk trial (SMILEE) has also started as a potential treatment for EoE, a food-allergy related disease. The EoE trial broadens DBV’s focus beyond traditional food allergy, which includes peanut, cow’s milk and hen’s egg allergy.
09 Dec 2015
Enlarged Phase III PEPITES study starts
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Enlarged Phase III PEPITES study starts
DBV Technologies SA (DBV:PAR) | 0 0 (-0.7%) | Mkt Cap: 1,056m
- Published:
09 Dec 2015 - Author:
-
Pages:
5
DBV has now started the Phase III Viaskin Peanut trial (PEPITES), which has been enlarged to meet patient and investigator demand, a positive sign for future potential uptake. The Phase II Viaskin Milk trial (SMILEE) has also started as a potential treatment for EoE, a food-allergy related disease. The EoE trial broadens DBV’s focus beyond traditional food allergy, which includes peanut, cow’s milk and hen’s egg allergy.